Deutsche Bank
OTLK icon

Deutsche Bank’s Outlook Therapeutics OTLK Stock Holding History

Deutsche Bank’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.14K Sell
2,000
-128,700
-98% -$123K ﹤0.01% 3600
2026
Q2 		$208K Buy
+130,700
New +$81.1K ﹤0.01% 3234
2025
Q3 		– Sell
-2,938
Closed -$4.7K – 3694
2025
Q2 		$4.7K Buy
2,938
+813
+38% +$1.3K ﹤0.01% 3530
2025
Q1 		$2.59K Buy
2,125
+1,419
+201% +$2.49K ﹤0.01% 3544
2024
Q4 		$1.33K Sell
706
-6,626
-90% -$27.3K ﹤0.01% 3571
2024
Q3 		$39.2K Hold
7,332
– – ﹤0.01% 3399
2024
Q2 		$54.1K Buy
7,332
+6,819
+1,329% +$54.7K ﹤0.01% 3311
2024
Q1 		$6.12K Sell
513
-1
-0.2% -$8 ﹤0.01% 3554
2023
Q4 		$4.01K Hold
514
– – ﹤0.01% 3577
2023
Q3 		$2.26K Sell
514
-2,662
-84% -$58.9K ﹤0.01% 3637
2023
Q2 		$111K Sell
3,176
-1,787
-36% -$48.7K ﹤0.01% 3226
2023
Q1 		$108K Buy
4,963
+2,405
+94% +$53.8K ﹤0.01% 3294
2022
Q4 		$55.2K Buy
2,558
+40
+2% +$870 ﹤0.01% 3536
2022
Q3 		$61K Sell
2,518
-396
-14% -$9.21K ﹤0.01% 3534
2022
Q2 		$60K Buy
2,914
+329
+13% +$9.46K ﹤0.01% 3707
2022
Q1 		$92K Sell
2,585
-505
-16% -$15.8K ﹤0.01% 3612
2021
Q4 		$84K Buy
3,090
+529
+21% +$18.9K ﹤0.01% 3776
2021
Q3 		$111K Sell
2,561
-39
-2% -$1.88K ﹤0.01% 3857
2021
Q2 		$129K Buy
+2,600
New +$121K ﹤0.01% 4031
2020
Q1 		– Sell
-1,285
Closed -$15K – 4680
2019
Q4 		$15K Buy
+1,285
New +$29.9K ﹤0.01% 4386
2019
Q3 		– Sell
-20
Closed – – 5163
2019
Q2 		$0 Sell
20
-538
-96% -$25.1K ﹤0.01% 5452
2019
Q1 		$82K Buy
+558
New +$78.8K ﹤0.01% 4372

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Gilpin Wealth Management
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $33B AUM 30.04% 1-Year Est. Return

Deutsche Bank's OTLK Position: Q3 2026 in Review

Deutsche Bank reduced its Outlook Therapeutics (OTLK) stake by 98% in Q3 2026, selling an estimated $123K and leaving 2,000 shares worth $1.14K. The position accounts for ﹤0.01% of the portfolio, ranked #3600.

Deutsche Bank first reported a position in OTLK in Q1 2019 and has held it in 22 quarters since. The position peaked at $208K in Q2 2026. 61 funds tracked by Wall St. Rank hold OTLK as of Q3 2026.

  • Deutsche Bank held 2,000 shares of Outlook Therapeutics worth $1.14K as of Q3 2026.
  • Deutsche Bank sold 128,700 Outlook Therapeutics shares in Q3 2026, an estimated $123K.
  • Outlook Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #3600 holding.
  • Deutsche Bank first reported a position in Outlook Therapeutics in Q1 2019 and has held it in 22 quarters since.
  • Deutsche Bank's Outlook Therapeutics position peaked at $208K in Q2 2026.
  • 61 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.